SCHEMBL4142229

SCHEMBL4142229

O=c1cnc2cccnc2n1CC1OCCO1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 13/20 0.42
HSD17B10 Q99714 6/20 0.42
KDM4E B2RXH2 4/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CYP1A2 P05177 11/20 0.40
HPGD P15428 3/20 0.40
CYP3A4 P08684 5/20 0.39
HIF1A Q16665 4/20 0.39
CASP1 P29466 2/20 0.39
CASP7 P55210 2/20 0.39
CLK4 Q9HAZ1 2/20 0.39
MAPK1 P28482 1/20 0.39
TSHR P16473 4/20 0.38
KMT2A Q03164 3/20 0.38
CYP2C19 P33261 3/20 0.38
MEN1 O00255 2/20 0.38
CYP2C9 P11712 5/20 0.37
LMNA P02545 2/20 0.37
HBB P68871 1/20 0.37
GLA P06280 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2795578 0.80 KDM4E (0.64) ALDH1A1HSD17B10KDM4ENPSR1HPGD
SCHEMBL4135731 0.79 ALDH1A1 (0.43) ALDH1A1HSD17B10KDM4ENPSR1CYP1A2
SCHEMBL4132770 0.79 CDK4 (0.39) KMT2A
SCHEMBL4136871 0.78 CYP1A2 (0.42) ALDH1A1HSD17B10KDM4ENPSR1CYP1A2
SCHEMBL12090527 0.78 CYP1A2 (0.45) ALDH1A1HSD17B10CYP1A2HPGDCYP3A4
SCHEMBL4137122 0.78 CYP1A2 (0.42) ALDH1A1HSD17B10KDM4ENPSR1CYP1A2
SCHEMBL4139913 0.76 KCNH2 (0.49) ALDH1A1HSD17B10CYP1A2HPGDCYP3A4
SCHEMBL4149971 0.75 ALDH1A1 (0.45) ALDH1A1HSD17B10KDM4ENPSR1CYP1A2
SCHEMBL4146157 0.75 ALDH1A1 (0.45) ALDH1A1HSD17B10KDM4ENPSR1CYP1A2
SCHEMBL12090780 0.74 KMT2A (0.42) ALDH1A1HSD17B10CYP1A2HPGDCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2022793-B1 NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF TOYAMA CHEMICAL CO LTD (JP) 2014-06-04 EP disclosed
US-8367831-B2 Heterocyclic compound or salt thereof and intermediate thereof TOYAMA CHEMICAL CO., LTD. (JP) 2013-02-05 US disclosed
US-8367831-B2 Heterocyclic compound or salt thereof and intermediate thereof TOYAMA CHEMICAL CO., LTD. (JP) 2013-02-05 US disclosed
US-8367831-B2 Heterocyclic compound or salt thereof and intermediate thereof TOYAMA CHEMICAL CO., LTD. (JP) 2013-02-05 US disclosed
US-20120226035-A1 NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-09-06 US disclosed
US-20120226035-A1 NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-09-06 US disclosed
US-20120226035-A1 NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-09-06 US disclosed
US-8211908-B2 Heterocyclic compound or salt thereof and intermediate thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-07-03 US disclosed
US-8211908-B2 Heterocyclic compound or salt thereof and intermediate thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-07-03 US disclosed
US-8211908-B2 Heterocyclic compound or salt thereof and intermediate thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-07-03 US disclosed
US-20090198063-A1 NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-08-06 US disclosed
US-20090198063-A1 NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-08-06 US disclosed
US-20090198063-A1 NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-08-06 US disclosed
EP-2022793-A1 NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-02-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090198063-A1 NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF IKZF3, ZC3HAV1L, H1-4 ALDH1A1 3789/4885HSD17B10 1478/4885KDM4E 1732/4885
US-20120226035-A1 NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF IKZF3, ZC3HAV1L, CXXC5 ALDH1A1 3409/4885HSD17B10 1172/4885KDM4E 1786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.